New hope for aggressive blood cancer: targeted combo shows promise
NCT ID NCT07257055
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study is for people with a newly diagnosed, aggressive type of blood cancer called mantle cell lymphoma (MCL). Researchers want to see if adding a drug called glofitamab after initial treatment with a BTK inhibitor and rituximab can better control the disease. About 30 participants will receive this combination and be monitored for side effects and cancer response. The goal is to improve outcomes for high-risk patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.